Clinical trial
A Single Center, Randomized, Double-blind , Single-dose, and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of MW032 and Xgeva® in Healthy Adults
NCT04798326 is registered in ClinicalTrials.gov with Mabwell (Shanghai) Bioscience Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Center, Randomized, Double-blind , Single-dose, and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of MW032 and Xgeva® in Healthy Adults
- Lead sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 25, 2019
- Completion date
- February 26, 2020
- Enrollment
- 120 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
bone tumor